Jan 6, 2026, 13:39
JAMA Neurology: No Added Benefit of Dual Therapy After Ischemic Stroke in Case of AFib
JAMA Neurology shared on LinkedIn:
”In patients with ischemic stroke and concurrent nonvalvular atrial fibrillation and ASCVD, adding an antiplatelet agent to anticoagulant therapy offered no net clinical benefit over anticoagulant monotherapy.
Read the full article in JAMA.
Article: Optimal Antithrombotics for Ischemic Stroke and Concurrent Atrial Fibrillation and Atherosclerosis. A Randomized Clinical Trial
Authors: Shuhei Okazaki, Kanta Tanaka, Yukako Yazawa et al.
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 8, 2026, 18:14Simon Fletcher: See The Unique Challenges PwH Face During Their Gene Therapy Journey
-
Apr 8, 2026, 17:56Hisam Siddiqi: Understanding Bone Marrow Trephine Morphology in MPNs
-
Apr 8, 2026, 17:46Mohamed Reda: Why Some Veins Decide to Take a ‘Detour’?
-
Apr 8, 2026, 17:39Managing Acquired Von Willebrand Syndrome in a Swine Polytrauma Model During ECLS – JTH
-
Apr 8, 2026, 17:04Heghine Khachatryan: Marfan vs LDS – Not All Aortopathies Are the Same
-
Apr 8, 2026, 17:00Frits Rosendaal Receives ISTH Grant Medal for Lifetime Contributions to Thrombosis and Hemostasis Field
-
Apr 8, 2026, 16:25Xiaoying Chen: Teleneurological Ward As A Practical Way to Support High-Quality Stroke Care Beyond Major Centres
-
Apr 8, 2026, 16:24Ney Carter Borges: Endocrine Drivers of Resistant Hypertension – Insights from the MOMENTUM Trial at ACC 26
-
Apr 8, 2026, 16:21Jonathan Gelber: Exploring Papaya Extract as an Option to Elevate Platelet Numbers Before PRP